Piper Sandler raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $540 from $400 and keeps an Overweight rating on the shares into Q3 earnings given REZDIFFRA’s strong launch trajectory and IP out to 2044. The firm also looks at growing strategic MASH interest, highlighting key contributing factors Piper thinks are driving growing appreciation and thus investments in the space. With this, the firm believes GLP-1 in MASH will ultimately expand the top of the funnel to increase REZDIFFRA’s TAM considering that GI/Heps tend to prefer liver-targeted therapies.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- Madrigal Pharmaceuticals: Strong Growth Potential Driven by Rezdiffra’s Market Leadership and Strategic Opportunities
- Madrigal Pharmaceuticals initiated with a Buy at Truist
- Madrigal Pharmaceuticals price target raised to $590 from $500 at Oppenheimer
- Madrigal Pharmaceuticals price target raised to $560 from $460 at B. Riley
- 3 Stocks Showing Strong Buy Signals, According to Technical Analysis